Company profile

Takeda Pharmaceutical Company

Diversified pharma / GI

TAK · NYSE · Japan

Share price · TAK

$18.05+1.48 (+8.93%) 3M

close as of 2026-08-18 · 24h delayed · vol 3.8M

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(15 total)
15Total Assets
6Approved
9Phase 3 / Filed
0Phase 1–2 / Early
9Diseases
Quick filter:
Showing 15 of 15 assets
Target & Modality
Alogliptin(Nesina)
Approved
DPP-4Small molecule
Type 2 Diabetes
Bortezomib
Approved
ProteasomeSmall molecule
Multiple Myeloma
Brigatinib
Approved
ALKSmall molecule
Non-Small Cell Lung Cancer
Ixazomib
Approved
ProteasomeSmall molecule
Multiple Myeloma
vedolizumab(Entyvio)
Approved
α4β7 integrinMonoclonal antibody
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease
Vortioxetine(Trintellix)
Approved
Serotonin transporter + multiple 5-HT receptorsSmall molecule
Major Depressive Disorder
Mezagitamab
Phase 3
CD38Monoclonal antibody
Multiple Myeloma
Omega-3-acid ethyl esters 90 (Lotriga)(Lotriga)No recent activity
Phase 3
Omega-3 fatty acid (EPA)Small molecule
Atherosclerotic Cardiovascular Disease
Osavampator
Phase 3
AMPA receptor (positive allosteric modulator)Small molecule
Major Depressive Disorder
Sapanisertib
Phase 3
mTORC1/mTORC2 (dual inhibitor)Small molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
SYR-472No recent activity
Phase 3
DPP-4Small molecule
Type 2 Diabetes
TAK-928
Phase 3
PD-1 (PDCD1) and IL-2Rα (CD25), dual-binding on tumor-specific CD8+ TSmall molecule
Non-Small Cell Lung Cancer
Trelagliptin(Zafatek)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Voglibose
Phase 3
Alpha-glucosidaseSmall molecule
Type 2 Diabetes
zasocitinib
Phase 3
TYK2Small molecule
Psoriatic ArthritisPsoriasis

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.